CD63 and cancer: In addition, the average count and heterogeneity of CD63 per CFSE+CD63+ sEV derived from the two cancer cell types (PC3 and A549) is notably higher than those in CFSE+CD63+ sEV derived from the two noncancerous cell types (RBC and HEK293).